Fortress Biotech, Inc. (FBIO) stock
FBIONasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as FBIOP
$1.88−0.11 (-5.53%)
Close on Nov 13, 2026Market cap $69.14MP/E –Yield –
Fortress Biotech r&d expenses
Research and development expenses are spending on new products and technology.
Fortress Biotech's R&D Expenses for the twelve months ending Sep 30, 2025 was $21.96M, down 61.3% year over year. For fiscal 2025 it was $11.90M, down 79.0% from the year before. Over ten years it grew -8.8% a year on average. The highest annual figure on record is $134.88M in fiscal 2022.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $11.90M | -79.0% |
| FY2024 | Dec 31, 2024 | $56.63M | -44.3% |
| FY2023 | Dec 31, 2023 | $101.75M | -24.6% |
| FY2022 | Dec 31, 2022 | $134.88M | +4.7% |
| FY2021 | Dec 31, 2021 | $128.87M | +101.0% |
| FY2020 | Dec 31, 2020 | $64.11M | -21.2% |
| FY2019 | Dec 31, 2019 | $81.33M | -6.9% |
| FY2018 | Dec 31, 2018 | $87.38M | +80.8% |
| FY2017 | Dec 31, 2017 | $48.32M | +37.5% |
| FY2016 | Dec 31, 2016 | $35.13M | +17.9% |
| FY2015 | Dec 31, 2015 | $29.81M | +191.1% |
| FY2014 | Dec 31, 2014 | $10.24M | -60.1% |
| FY2013 | Dec 31, 2013 | $25.68M | +47.0% |
| FY2012 | Dec 31, 2012 | $17.47M | +103.5% |
| FY2011 | Dec 31, 2011 | $8.58M | +2.9% |
| FY2010 | Dec 31, 2010 | $8.34M | +267.4% |
| FY2009 | Dec 31, 2009 | $2.27M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $1.68M | -79.4% |
| Q2 FY2026 | Jun 30, 2026 | $805.00K | -79.6% |
| Q1 FY2026 | Mar 31, 2026 | $540.00K | -94.4% |
| Q3 FY2025 | Sep 30, 2025 | $208.00K | -97.8% |
| Q2 FY2025 | Jun 30, 2025 | $8.13M | -35.9% |
| Q1 FY2025 | Mar 31, 2025 | $3.94M | -84.1% |
| Q4 FY2024 | Dec 31, 2024 | $9.69M | -0.7% |
| Q3 FY2024 | Sep 30, 2024 | $9.45M | -53.6% |
| Q2 FY2024 | Jun 30, 2024 | $12.67M | -60.6% |
| Q1 FY2024 | Mar 31, 2024 | $24.84M | -37.1% |
| Q4 FY2023 | Dec 31, 2023 | $9.75M | -72.2% |
| Q3 FY2023 | Sep 30, 2023 | $20.35M | -32.0% |
| Q2 FY2023 | Jun 30, 2023 | $32.14M | -3.0% |
| Q1 FY2023 | Mar 31, 2023 | $39.51M | +7.6% |
| Q4 FY2022 | Dec 31, 2022 | $35.12M | -18.4% |
| Q3 FY2022 | Sep 30, 2022 | $29.90M | +6.5% |
| Q2 FY2022 | Jun 30, 2022 | $33.13M | -2.1% |
| Q1 FY2022 | Mar 31, 2022 | $36.72M | +82.2% |
| Q4 FY2021 | Dec 31, 2021 | $43.05M | +139.7% |
| Q3 FY2021 | Sep 30, 2021 | $28.08M | +104.1% |
| Q2 FY2021 | Jun 30, 2021 | $33.83M | +95.9% |
| Q1 FY2021 | Mar 31, 2021 | $20.15M | +33.3% |
| Q4 FY2020 | Dec 31, 2020 | $17.96M | -28.1% |
| Q3 FY2020 | Sep 30, 2020 | $13.76M | -5.6% |
| Q2 FY2020 | Jun 30, 2020 | $17.27M | -6.7% |
| Q1 FY2020 | Mar 31, 2020 | $15.12M | -35.0% |
| Q4 FY2019 | Dec 31, 2019 | $24.97M | -13.5% |
| Q3 FY2019 | Sep 30, 2019 | $14.57M | -9.4% |
| Q2 FY2019 | Jun 30, 2019 | $18.51M | +5.8% |
| Q1 FY2019 | Mar 31, 2019 | $23.27M | -6.8% |
| Q4 FY2018 | Dec 31, 2018 | $28.86M | -40.2% |
| Q3 FY2018 | Sep 30, 2018 | $16.08M | +91.4% |
| Q2 FY2018 | Jun 30, 2018 | $17.49M | -50.2% |
| Q1 FY2018 | Mar 31, 2018 | $24.96M | – |
| Q4 FY2017 | Dec 31, 2017 | $48.27M | – |
| Q1 FY2017 | Mar 31, 2017 | $8.40M | – |
| Q4 FY2016 | Dec 31, 2016 | $35.13M | – |
See a number that looks wrong?